Items tagged with Drug-resistant TB
WHO webinar on 2018 DR-TB guidelines with TB stakeholders (post)
The World Health Organization (WHO) Task Force to support country transition towards new recommendations for the treatment of drug-resistant TB (DR-TB), created in August 2018, invites all interested TB stakeholders to participate in a webinar hosted by the WHO Global TB Program on 22 May 2019 from 14:00 to 15:30 (Central European Summer Time).
Breaking the cycle: Paediatric DR-TB detection, care and treatment in Tajikistan (post)
The Tajik Ministry of Health and Médecins Sans Frontières (MSF) began a comprehensive paediatric tuberculosis (TB) care programme in 2011. The paediatric TB project in Dushanbe aims to decrease the TB morbidity and mortality rates among children and their family members. In 2013, MSF documented this, producing a report about improving paediatric TB care.
Researchers study resistance to ‘protect’ anti-TB drug (post)
Scientists from Stellenbosch University are trying to conserve the life-saving treatment bedaquiline, by studying how the bacterium that causes TB can develop resistance to this drug.
Drug-resistant tuberculosis reversed in lab (post)
About 1.5 million people died of tuberculosis (TB) in 2017, making it the most lethal infectious disease worldwide. A growing rise in drug-resistant TB is a major obstacle to successfully treating the illness.
A raging TB epidemic in Papua New Guinea threatens to destabilize the entire Asia Pacific (post)
In Papua New Guinea, a TB epidemic threatens to turn into a disaster that could destabilize the Asia Pacific region. Situated about 90 miles from Australia in the Pacific Ocean, the island nation sees more than 100 cases of TB every day.
Stanford researchers synthesize healing compounds in scorpion venom (post)
Stanford chemists have identified and synthesized two new healing compounds in scorpion venom that are effective at killing staph and tuberculosis bacteria.
NIH launches large TB prevention trial for people exposed to multidrug-resistant TB (post)
A large clinical trial to assess treatments for preventing people at high risk from developing multidrug-resistant tuberculosis (MDR-TB) has begun. The study is comparing the safety and efficacy of a new MDR-TB drug, delamanid, with the decades-old TB drug isoniazid for preventing active MDR-TB disease in children, adolescents and adults at high risk who are exposed to adult household members with MDR-TB. Study participants are at high risk for MDR-TB because they either have latent TB infection, immune systems suppressed by HIV or other factors, or are younger than age 5 years and therefore have a weak immune system.
Unitaid’s investment in TB hits record levels with new grant for diagnostic technologies (post)
Geneva – The Foundation for Innovative New Diagnostics (FIND) and Unitaid signed a US$ 14.5 million grant Thursday (July 4) to deploy a powerful new technology in the diagnosis of drug-resistant tuberculosis.
The fight against TB: researchers at St. Michael’s Hospital identify best practices for the use of antibiotics (post)
Toronto, Canada , July 4, 2019 - Tuberculosis (TB) could develop resistance to rifampin – a crucial antibiotic – if clinicians aren’t vigilant about properly assessing patients for the active form of disease, suggests a paper written by St. Michael’s Hospital scientists and published in the Canadian Medical Association Journal.
Will a new TB treatment be available soon? (post)
MANILA — Experts advising the U.S. Food and Drug Administration on marketed and investigational drugs for infectious diseases and disorders were divided on whether the regulatory agency should approve a new drug as part of a proposed combination therapy for highly resistant tuberculosis.
Page 60 of 117 · Total posts: 0
←First 59 60 61 Last→